Eli Lilly is rated Sell/Avoid due to extreme overvaluation and waning technical momentum, despite robust GLP-1-driven growth. LLY trades at 29x trailing EV/EBITDA and 23.7x forward 2027 P/E ...

*Gulp* Much to the relief of the needle-shy, the FDA has just approved a second oral GLP-1 drug, following the release of the ...

FDA issues guidance compounded GLP-1 production limits, restricting pharmacies to compound only during active shortages to ...

Nutrition shakes have a unique opportunity to cater for GLP-1 users: and delivering the right nutritional profile will be key ...

A new type of daily pill has proven more effective for weight loss and blood sugar control than its currently available ...

You can now choose between GLP-1 pills or shots for weight loss. Here's what you need to know to decide which one is best for ...

Glucagon-like peptide-1 receptor agonists (GLP-1s) are a class of medication that includes Ozempic®, Wegovy®, and Saxenda®. Some GLP-1s are diabetes drugs, but you can also take a GLP-1 for weight ...

Common GLP-1s include semaglutides like Ozempic and Wegovy, and tirzepatides like Zepbound and Mounjaro. These drugs work by mimicking a natural hormone to regulate appetite, blood sugar, and feelings ...

Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." ...

Back in 2023, when Oobli started pushing out its line of sweet teas and chocolates to gain attention for its precision-fermented sweetener, being at the intersection of protein and a healthier ...